OptimizeRx reported Q3 2026 revenue of $21.6 million, down 17% year-over-year, but net income rose to $1.2 million. Adjusted EBITDA increased 23% to $6.3 million, reflecting improved margins and cost management. The company updated its 2026 revenue guidance to $87-$93 million while maintaining adjusted EBITDA guidance at $21-$25 million. Despite lower current-year revenue, OptimizeRx sees growth opportunities for 2027 with expanding contracts and AI-driven platform advantages, positioning it for sustainable growth.
OptimizeRx's Q3 2026 financial results provide context for healthcare sector trends. For readers following health stocks, here is Pluang's market snapshot as of Nov 12, 2026 04:11 WIB: out of 150 priced health-sector US stocks, 87 rose and 61 fell. Notable movers include HIMS at USD 20.79 with an 8.68% gain, ABEO down 8.35% at USD 2.25, and LQDA up 7.08% at USD 55.04.
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Shurgard Self Storage, a leading European self-storage REIT, is currently trading at a significant discount to its net tangible assets (NTA) with a valuation of 0.48x NTA. It offers an attractive dividend yield of 4.5% and benefits from strong urbani...
Kiniksa Pharmaceuticals International, plc announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026. The event will be webcast live and available for replay on the ...
Lakefront Biotherapeutics reported a net profit of €13.9 million for the first nine months of 2026, a significant turnaround from a €461.3 million loss in the same period last year. The company highlighted progress with its autoimmune drug gamgertami...
